Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
everolimus + pemetrexed
- Development stage
- Phase 1
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral (everolimus), Intravenous (pemetrexed)
01
Overview
Everolimus + pemetrexed is an investigational combination therapy consisting of everolimus, an mTOR (mammalian target of rapamycin) inhibitor, and pemetrexed, a folate antimetabolite chemotherapy agent. Everolimus inhibits the mTOR pathway, which regulates cell growth and proliferation. Pemetrexed inhibits several enzymes involved in purine and pyrimidine synthesis, primarily thymidylate synthase, thereby disrupting DNA replication in rapidly dividing tumor cells. This combination has been studied primarily for advanced non-small cell lung cancer (NSCLC), particularly after failure of prior chemotherapy regimens. Clinical studies have evaluated its safety profile and preliminary efficacy in this setting[1][2][5].
02
Targets
DHFR (Dihydrofolate reductase)TS (Thymidylate synthase)Mechanistic target of rapamycin complex 1
Beyond the preview
Go deeper on everolimus + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on everolimus + pemetrexed.